Change in opioid dose and change in depression in a longitudinal primary care patient cohort

Jeffrey F. Scherrer, Joanne Salas, Patrick J. Lustman, Sandra Burge, F. David Schneider

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Depression is associated with receipt of higher doses of prescription opioids. It is not known whether the reverse association exists in that an increased opioid dose is associated with increased depression. Questionnaires were administered to 355 patients with chronic low back pain at baseline and 1-year and 2-year follow-up. Depression, pain, anxiety, health-related quality of life, and social support or stresswere obtained by survey. Opioid type and dose and comorbid conditionswere derived fromchart abstraction.Randomintercept, generalized linearmixedmodelswere computed to estimate the association between change in opioidmorphine equivalent dose (MED) thresholds (0, 1-50, >50 mg) and probability of depression over time. Second, we computed the association between change in depression and odds of an increasing ME Dover time. After adjusting for covariates, an increase to>50 mg MED fromnonuse increased a participant's probability of depression over time (odds ratio [OR] = 2.65; 95% confidence interval [CI], 1.17-5.98). An increase to 1 to 50mg MED did not increase an individual's probability of depression over time (OR51.08; 95% CI, 0.65-1.79). In unadjusted analysis, developing depression was associated with a 2.13 (95% CI, 1.36-3.36) increased odds of a higher MED. This association decreased after adjusting for all covariates (OR=1.65; 95%CI, 0.97-2.81). Post hoc analysis revealed that depression was significantly associated with a 10.1-mgMEDincrease in fully adjustedmodels.Change to a higherMEDleads to an increased risk of depression, and developing depression increases the likelihood of a higherMED.We speculate that treating depression or loweringMEDmay mitigate a bidirectional association and ultimately improve pain management.

Original languageEnglish (US)
Pages (from-to)348-355
Number of pages8
JournalPain
Volume156
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Opioid Analgesics
Primary Health Care
Depression
Confidence Intervals
Odds Ratio
Pain Management
Low Back Pain
Social Support
Prescriptions
Anxiety
Quality of Life
Pain

Keywords

  • Cohort
  • Depression
  • Epidemiology
  • Opioids

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Change in opioid dose and change in depression in a longitudinal primary care patient cohort. / Scherrer, Jeffrey F.; Salas, Joanne; Lustman, Patrick J.; Burge, Sandra; David Schneider, F.

In: Pain, Vol. 156, No. 2, 01.01.2015, p. 348-355.

Research output: Contribution to journalArticle

Scherrer, Jeffrey F. ; Salas, Joanne ; Lustman, Patrick J. ; Burge, Sandra ; David Schneider, F. / Change in opioid dose and change in depression in a longitudinal primary care patient cohort. In: Pain. 2015 ; Vol. 156, No. 2. pp. 348-355.
@article{1550f6081afa405b981c7dccd8f0ee44,
title = "Change in opioid dose and change in depression in a longitudinal primary care patient cohort",
abstract = "Depression is associated with receipt of higher doses of prescription opioids. It is not known whether the reverse association exists in that an increased opioid dose is associated with increased depression. Questionnaires were administered to 355 patients with chronic low back pain at baseline and 1-year and 2-year follow-up. Depression, pain, anxiety, health-related quality of life, and social support or stresswere obtained by survey. Opioid type and dose and comorbid conditionswere derived fromchart abstraction.Randomintercept, generalized linearmixedmodelswere computed to estimate the association between change in opioidmorphine equivalent dose (MED) thresholds (0, 1-50, >50 mg) and probability of depression over time. Second, we computed the association between change in depression and odds of an increasing ME Dover time. After adjusting for covariates, an increase to>50 mg MED fromnonuse increased a participant's probability of depression over time (odds ratio [OR] = 2.65; 95{\%} confidence interval [CI], 1.17-5.98). An increase to 1 to 50mg MED did not increase an individual's probability of depression over time (OR51.08; 95{\%} CI, 0.65-1.79). In unadjusted analysis, developing depression was associated with a 2.13 (95{\%} CI, 1.36-3.36) increased odds of a higher MED. This association decreased after adjusting for all covariates (OR=1.65; 95{\%}CI, 0.97-2.81). Post hoc analysis revealed that depression was significantly associated with a 10.1-mgMEDincrease in fully adjustedmodels.Change to a higherMEDleads to an increased risk of depression, and developing depression increases the likelihood of a higherMED.We speculate that treating depression or loweringMEDmay mitigate a bidirectional association and ultimately improve pain management.",
keywords = "Cohort, Depression, Epidemiology, Opioids",
author = "Scherrer, {Jeffrey F.} and Joanne Salas and Lustman, {Patrick J.} and Sandra Burge and {David Schneider}, F.",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/01.j.pain.0000460316.58110.a0",
language = "English (US)",
volume = "156",
pages = "348--355",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Change in opioid dose and change in depression in a longitudinal primary care patient cohort

AU - Scherrer, Jeffrey F.

AU - Salas, Joanne

AU - Lustman, Patrick J.

AU - Burge, Sandra

AU - David Schneider, F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Depression is associated with receipt of higher doses of prescription opioids. It is not known whether the reverse association exists in that an increased opioid dose is associated with increased depression. Questionnaires were administered to 355 patients with chronic low back pain at baseline and 1-year and 2-year follow-up. Depression, pain, anxiety, health-related quality of life, and social support or stresswere obtained by survey. Opioid type and dose and comorbid conditionswere derived fromchart abstraction.Randomintercept, generalized linearmixedmodelswere computed to estimate the association between change in opioidmorphine equivalent dose (MED) thresholds (0, 1-50, >50 mg) and probability of depression over time. Second, we computed the association between change in depression and odds of an increasing ME Dover time. After adjusting for covariates, an increase to>50 mg MED fromnonuse increased a participant's probability of depression over time (odds ratio [OR] = 2.65; 95% confidence interval [CI], 1.17-5.98). An increase to 1 to 50mg MED did not increase an individual's probability of depression over time (OR51.08; 95% CI, 0.65-1.79). In unadjusted analysis, developing depression was associated with a 2.13 (95% CI, 1.36-3.36) increased odds of a higher MED. This association decreased after adjusting for all covariates (OR=1.65; 95%CI, 0.97-2.81). Post hoc analysis revealed that depression was significantly associated with a 10.1-mgMEDincrease in fully adjustedmodels.Change to a higherMEDleads to an increased risk of depression, and developing depression increases the likelihood of a higherMED.We speculate that treating depression or loweringMEDmay mitigate a bidirectional association and ultimately improve pain management.

AB - Depression is associated with receipt of higher doses of prescription opioids. It is not known whether the reverse association exists in that an increased opioid dose is associated with increased depression. Questionnaires were administered to 355 patients with chronic low back pain at baseline and 1-year and 2-year follow-up. Depression, pain, anxiety, health-related quality of life, and social support or stresswere obtained by survey. Opioid type and dose and comorbid conditionswere derived fromchart abstraction.Randomintercept, generalized linearmixedmodelswere computed to estimate the association between change in opioidmorphine equivalent dose (MED) thresholds (0, 1-50, >50 mg) and probability of depression over time. Second, we computed the association between change in depression and odds of an increasing ME Dover time. After adjusting for covariates, an increase to>50 mg MED fromnonuse increased a participant's probability of depression over time (odds ratio [OR] = 2.65; 95% confidence interval [CI], 1.17-5.98). An increase to 1 to 50mg MED did not increase an individual's probability of depression over time (OR51.08; 95% CI, 0.65-1.79). In unadjusted analysis, developing depression was associated with a 2.13 (95% CI, 1.36-3.36) increased odds of a higher MED. This association decreased after adjusting for all covariates (OR=1.65; 95%CI, 0.97-2.81). Post hoc analysis revealed that depression was significantly associated with a 10.1-mgMEDincrease in fully adjustedmodels.Change to a higherMEDleads to an increased risk of depression, and developing depression increases the likelihood of a higherMED.We speculate that treating depression or loweringMEDmay mitigate a bidirectional association and ultimately improve pain management.

KW - Cohort

KW - Depression

KW - Epidemiology

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=84977669122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977669122&partnerID=8YFLogxK

U2 - 10.1097/01.j.pain.0000460316.58110.a0

DO - 10.1097/01.j.pain.0000460316.58110.a0

M3 - Article

VL - 156

SP - 348

EP - 355

JO - Pain

JF - Pain

SN - 0304-3959

IS - 2

ER -